Q3 2025 13F Holders as of 30 Sep 2025
-
Type / Class
-
Equity / COMMON STOCK
-
Shares outstanding
-
113M
-
Number of holders
-
360
-
Total 13F shares, excl. options
-
71.2M
-
Shares change
-
-4.92M
-
Total reported value, excl. options
-
$1.87B
-
Value change
-
-$130M
-
Put/Call ratio
-
0.54
-
Number of buys
-
187
-
Number of sells
-
-171
-
Price
-
$26.28
Significant Holders of Viking Therapeutics, Inc. - COMMON STOCK (VKTX) as of Q3 2025
470 filings reported holding VKTX - Viking Therapeutics, Inc. - COMMON STOCK as of Q3 2025.
Viking Therapeutics, Inc. - COMMON STOCK (VKTX) has 360 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 71.2M shares
of 113M outstanding shares and own 62.94% of the company stock.
Largest 10 shareholders include VANGUARD GROUP INC (10M shares), FMR LLC (5.79M shares), BlackRock, Inc. (5.6M shares), STATE STREET CORP (4.51M shares), MORGAN STANLEY (3.73M shares), JPMORGAN CHASE & CO (2.58M shares), SUSQUEHANNA INTERNATIONAL GROUP, LLP (2.1M shares), AMERIPRISE FINANCIAL INC (2.09M shares), TWO SIGMA INVESTMENTS, LP (2.09M shares), and CITADEL ADVISORS LLC (1.9M shares).
This table shows the top 360 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.